Transforming interventional cardiology with 24/7/365 live procedures from top global sites and experts. @SameerMehtaMD Founder & CEO Powered by Lumen Foundation
🧠"La psicología de los intervencionistas de oclusiones crónicas y lesiones complejas". @pipecardio @AJuradoRoman y @RumoJose
Ya disponible en Spotify:
https://t.co/CqiWh6RIIB
We are proud to announce that Mount Sinai Heart at The Mount Sinai Hospital is ranked No. 4 in the nation for Cardiology and Heart Surgery by U.S. News & World Report® for 2023-24.
@usnews
🫀 We are happy and grateful for the opportunity given of being selected as one of the institutions who participated in one the first interventional cardiology stream program.
Congrats to the whole team @Hemodin_LaPaz. let it be the first of further collabs @MedStream360
Medstream 360 pilot completed: 227 spectacular cases from 12 global sites, no major complications. 47% coronary, 37% structural, 7% adult congenital, 9% endovascular. See 3 min summary: https://t.co/u4LCpQvZP1
Phase 2 with 20 sites begins soon.
Updates on beta-blocker use, revascularization and routine testing and recommendations on healthy lifestyle are among the highlights of a new guideline on the management of chronic coronary disease @virani_md@AKUGlobal@BCMHeart@SVRaoMD#cardiotwitter https://t.co/Q4zPwkp2yg
After transfemoral #TAVR with a self-expanding device, the need for a pacemaker was common & impactful for mortality, according to a new study in #JACCINT. @cphend covers the findings in @medpagetoday: https://t.co/SqkvarzZjo
We have completed the pilot stage of @medstream360 with these impressive numbers. There 24 hours of continuous live streaming one day per week for 12 weeks from different centers around the 🌎 from China to California en USA. 🧵
ICYMI: "Our study provides valuable insights on how the prognosis of women undergoing PCI is affected by the interaction between diabetes and CKD" @EuroInterventio#EuroPCR@PCRonline#cardiotwitter https://t.co/rmNOvlJ4mK
ICYMI: “Our analysis provides evidence that supports the feasibility and safety of TAVR in patients with obesity” #cardiotwitter https://t.co/pVAIBg4vxG